Loading news...
NexGel (NASDAQ: NXGL - Get Free Report) is expected to be releasing its Q4 2025 results after the market closes on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $3.24 million for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for the
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing
The transaction represents the most significant milestone in the company's history.
Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and NexGel (NASDAQ: NXGL - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Valuation and Earnings This table compares
LANGHORNE, Pa. , Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.
NexGel (NASDAQ: NXGL - Get Free Report) and Teleflex (NYSE: TFX - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends. Profitability This table compares NexGel and Teleflex's net margins, return
LANGHORNE, Pa. , Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company's previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC.
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off
NEXGEL, Inc. ( NXGL ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants Adam Levy - CEO, President & Director Joseph McGuire - Chief Financial Officer Conference Call Participants Valter Pinto - Kanan, Corbin, Schupak & Aronow, Inc. Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Good afternoon, everyone. My name is Bo, and I will be your conference operator today.
LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
NEXGEL, Inc. (NASDAQ:NXGL ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam R. Levy - CEO, President & Director Joseph F.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors.
LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 413,044 shares of its common stock (the “Shares”) at $2.30 a share. In a concurrent private placement, NEXGEL also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 206,522 shares of common stock (the “Unregistered Warrants”). The Unregistered Warrants will have an exercise price of $4.25 per share and are exercisable immediately upon issuance with a term of five years from the date of issuance.
LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced expanding its partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. The expansion includes the planned launch of digestive enzyme formulas and solutions targeting scars and stretch marks.
NEXGEL, Inc. (NASDAQ:NXGL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Eric Ramos - Titan Capital Management Operator Good afternoon. I will be your conference operator today.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL, Inc. (NASDAQ:NXGL ) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive Officer Joe McGuire - Chief Financial Officer Conference Call Participants Naz Rahman - Maxim Group Operator Good afternoon. I will be your conference operator today.